The Novaplex MPXV Assay is a real-time polymerase chain reaction (PCR) product that specifically detects the monkeypox virus target gene using the company’s TOCE technology.
It has been developed using Seegene’s artificial intelligence (AI)-based automated test development system, called Seegene Digitalized Development System (SGDDS), and technologies.
Used as a confirmation test for monkeypox virus infection, the assay provides a convenient workflow with a streamlined automation system.
The test can identify positive monkeypox virus cases within 90 minutes of testing.
According to the World Health Organization (Who ), the monkeypox virus is an evolving health threat, which needs collective attention and coordinated action. The organisation has urged member states to increase surveillance, contact tracing and testing.
Seegene CEO Dr Jong-Yoon Chun said: “The monkeypox virus outbreak shows that endemic viruses can rapidly spread to the rest of the world and it’s a warning that new pandemics can emerge and threaten our lives at any time.
“We will continue our efforts to develop products that can accurately diagnose any virus to help prevent new infectious diseases from taking hold and becoming a pandemic.”
The company stated that it has developed the new Novaplex MPXV Assay to help control the spread of the virus across the world.
It is planning to provide the new assay to countries that have detected the virus.
In April, Seegene received approval from Australia’s Therapeutic Goods Administration (TGA) for its Allplex RV Master Assay, which can identify three Covid-19 genes, as well as Flu A, Flu B and metapneumovirus.